Abstract
The distribution of the central benzodiazepine receptor specific ligand iodine-123 iomazenil was investigated in seven human adults from whole-body scans, blood samples and urine collected up to 24 h after injection. Using 12 source organs, the MIRD method was applied to calculate the absorbed radiation dose of the radioligand in various organs. The urinary bladder wall (0.15 mGy/MBq), lower large intestinal wall (0.071 mGy/MBq) testes (0.044 mGy/MBq) and upper large intestined wall (0.038 mGy/MBq) received the highest absorbed doses. The average effective dose equivalent of 123I-IBZM for adults was estimated to be 0.033 mSv/MBq.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beer HF, Bläuenstein PA, Hasler PH, Delaloye B, Riccabona G, Bangerl I, Hunkeler W, Bonetti EP, Pieri L, Richards JG, Schubiger PA. In vitro and in vivo evaluation of iodine-123-Ro 16–0154: a new imaging agent for SPELT investigations of benzodiazepine receptors. J Nucl Med 1990; 31:1007–1014.
Verhoeff NPLG, Van Royen EA, Ell PJ, Costa DC, Hasler PH, Schubiger PA. Benzodiazepine receptor density in human brain measured in vivo with 123-I-Iomazenil SPECT. Nucl Med 1991;Suppl 27:203–206.
Verhoeff NPLG. Van Royen EA, Overweg J, Limburg M, Stam J, Roolker L, Wiggerts HO, Beer HF. Dynamic studies of the binding of 1231-Iomazenil to central benzodiazepine receptors in healthy volunteers. Nucl Med 1992; Suppl 28:175–178
Bartenstein P, Ludolph A, Schober O, Lottes G, Scheidhauer K, Sciuk J, Beer HF. Benzodiazepine receptors and cerebral blood flow in partial epilepsy. Eur J Nucl Med 1991; 18:111–118.
Schubiger PA, Hasler PH, Beer-Wohlfahrt H, Bejier A, Oettli R, Cordes M, Ferstl F, Deisenhammer E, De Roo M, Moser E, Nitzsche E, Podreka I, Riccabona G, Banged I, Schober O, Bartenstein P, Van Rijk P, Van Isselt JW, Van Royen EA, Verhoeff NPLG, Haldemann R, Von Schultess GK. Evaluation of a multicentre study with Iomazenil — a benzodiazepine receptor ligand. Nucl Med Commun 1991; 12:569–582.
Verhoeff NPLG, Van Royen EA, Overweg J, Gutter T, Beer HF. Central benzodiazepine receptor imaging with 123I-Iomazenil SPECT combined with EEG in patients with partial epilepsy. Nucl Med 1992; Suppl 28:179–182.
Dey HM, Woods SW, Goddard AW, Seibyl JP, Baldwin RM, Zubal G, Smith EO, Hoffer PB, Innis RB. In vivo distribution of the SPELT benzodiazepine receptor ligand I-123 RO 160154 in man [abstract]. J Nucl Med 1991; 32:1043.
Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys 1973;25:147–161.
Loevinger R, Budinger TF, Watson EE, et al. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine, 1990.
Johansson L, Mattson S, Nosslin B. Effective dose equivalent from radiopharmaceuticals. Eur J Nucl Med 1984; 9:485–489.
Haefely WE. The story and activity of flumazenil (Anexate®). Acta Anaesthesiol Belg 1989; 40:3–9.
Persson A, Ehrin E, Eriksson L, Farde L, Hedström CG, Litton JE, Mindus P, Sedvall G. Imaging of [11C]-labelled Ro 15–1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. J Psychiatr Res 1985; 19:609–622.
Pappata S, Samson Y, Chavoix C, Prenant C, Mazière M, Baron JC. Regional specific binding of (11C) Ro 15–1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J Cereb Blood Flow Metab 1988; 8:304–313.
Savic I, Roland P, Sedvall G, Persson A, Pauli S, Widén L. In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 1988; II: 863–866.
Mettler FA Jr, Christie JH, Williams AG Jr, Moseley RD Jr, Kesley CA. Population characteristics and absorbed dose to the population from nuclear medicine: United States-1982. Health Phys 1986; 50:619–628.
Beekhuis H. Population radiation absorbed dose from nuclear medicine procedures in the Netherlands. Health Phys 1988; 54:287–291.
World Health Organisation Technical Report Series 611. Use of ionizing radiation and radionuclides on human beings for medical research, training, and nonmedical purposes. Report of a WHO expert Committee, Geneva, 1977.
Verhoeff NPLG, Erbas B, Kapucu O, Busemann Sokole E, Blok H, Van Royen EA. Quantification of central benzodiazepine receptor binding potential in the brain with 123I-iomazenil SPECT: technical and inter-observer variability. Nucl Med Commun (in press)
United States General Services Administration. Code of Federal Regulations. Chapter 21, Part 361. Prescription drugs for human use generally recognized as safe and effective and not misbranded: drugs used in research. Washington, DC: US Government Printing Office; 1992:221–226.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Verhoeff, N.P.L.G., Busemann Sokole, E., Hengst, D. et al. Dosimetry of iodine-123 iomazenil in humans. Eur J Nucl Med 20, 580–584 (1993). https://doi.org/10.1007/BF00176551
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00176551